Literature DB >> 1094226

[Experience with fractionate massive-dose Ifosfamid therapy of generalized malignant tumors].

H Hoefer-Janker, W Scheef, U Günther, W Hüls.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1094226

Source DB:  PubMed          Journal:  Med Welt        ISSN： 0025-8512


× No keyword cloud information.
  7 in total

1.  6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.

Authors:  E C Brain; A Mita; P Soulié; H Errihani; A C Hardy Bessard; M Chaouche; J Alexandre; J P Delord; E Cvitkovic; C Jasmin; J L Misset
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.

Authors:  P H Willemse; M E vd Burg; A vd Gaast; J P Neijt; W W ten Bokkel Huinink; J G Aalders; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma.

Authors:  M E Heim; R Fiene; E Schick; E Wolpert; W Queisser
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

4.  Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.

Authors:  V H Bramwell; H T Mouridsen; A Santoro; G Blackledge; R Somers; D Thomas; R Sylvester; A Van Oosterom
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer.

Authors:  N Gad-el-Mawla; M R Hamza; Z K Zikri; M Elserafi; A el-Khodari; H Khaled; R Gafaar
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.

Authors:  M Fukuoka; S Negoro; N Masuda; K Furuse; M Kawahara; N Kodama; H Ikegami; S Nakamura; H Nishio; T Ohnoshi
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 7.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.